Published in

Taylor and Francis Group, Cancer Investigation, 4(32), p. 144-149, 2014

DOI: 10.3109/07357907.2014.885984

Links

Tools

Export citation

Search in Google Scholar

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Journal article published in 2014 by Paolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, Michele Del Vecchio ORCID, Michele Del Vecchio, Paolo Marchetti, Gian Carlo Antonini Cappellini, Francesco de Rosa, G. C. Antonini, Ruggero Ridolfi, F. D. Rosa, Francesco Cognetti, Virginia Ferraresi, Alessandro Testori, Paola Queirolo ORCID and other authors.
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Red circle
Preprint: archiving forbidden
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Of 93 patients with pretreated, BRAF(V600) mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment with ipilimumab 3 mg/kg, median overall survival (mOS) from first treatment was 9.9 and 14.5 months, respectively. Among patients treated with a BRAF inhibitor first, mOS from the end of BRAF inhibition was 1.2 months for those who did not complete ipilimumab treatment as per protocol, compared with 12.7 months for those who did (p < .001). Prospective, randomized studies are required to determine the optimal sequencing of ipilimumab and BRAF inhibitors in patients with BRAF-mutated metastatic melanoma.